Abstract
To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.
| Original language | English |
|---|---|
| Pages (from-to) | 1279-1286 |
| Number of pages | 8 |
| Journal | Japanese Journal of Cancer Research |
| Volume | 93 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 01-12-2002 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
}
Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death : A case-control study nested in the Japan Collaborative Cohort (JACC) study. / Wakai, Kenji; Ito, Yoshinori; Suzuki, Koji; Tamakoshi, Akiko; Seki, Nao; Ando, Masahiko; Ozasa, Kotaro; Watanabe, Yoshiyuki; Kondo, Takaaki; Nishino, Yoshikazu; Ohno, Yoshiyuki; Mori, M.; Motohashi, Y.; Tsuji, I.; Nakamura, Y.; Iso, H.; Mikami, H.; Hashimoto, S.; Inaba, Y.; Hoshiyama, Y.; Suzuki, H.; Shimizu, H.; Toyoshima, H.; Tokudome, S.; Kikuchi, S.; Koizumi, A.; Kawamura, T.; Miki, T.; Dale, C.; Sakata, K.; Nose, T.; Hayakawa, N.; Yoshimura, T.; Fukuda, K.; Okamoto, N.; Shio, H.; Kitagawa, T.; Kuroki, T.; Tajima, K.; Shimamoto, T.; Tanaka, H.; Hisamichi, S.; Nakao, M.; Suzuki, T.; Hashimoto, T.; Ishibashi, T.; Aoki, Kunio; Sugano, Haruo; Nakachi, Kei; Hashimoto, Shuji.
In: Japanese Journal of Cancer Research, Vol. 93, No. 12, 01.12.2002, p. 1279-1286.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Serum insulin-like growth factors, insulin-like growth factor-binding protein-3, and risk of lung cancer death
T2 - A case-control study nested in the Japan Collaborative Cohort (JACC) study
AU - Wakai, Kenji
AU - Ito, Yoshinori
AU - Suzuki, Koji
AU - Tamakoshi, Akiko
AU - Seki, Nao
AU - Ando, Masahiko
AU - Ozasa, Kotaro
AU - Watanabe, Yoshiyuki
AU - Kondo, Takaaki
AU - Nishino, Yoshikazu
AU - Ohno, Yoshiyuki
AU - Mori, M.
AU - Motohashi, Y.
AU - Tsuji, I.
AU - Nakamura, Y.
AU - Iso, H.
AU - Mikami, H.
AU - Hashimoto, S.
AU - Inaba, Y.
AU - Hoshiyama, Y.
AU - Suzuki, H.
AU - Shimizu, H.
AU - Toyoshima, H.
AU - Tokudome, S.
AU - Kikuchi, S.
AU - Koizumi, A.
AU - Kawamura, T.
AU - Miki, T.
AU - Dale, C.
AU - Sakata, K.
AU - Nose, T.
AU - Hayakawa, N.
AU - Yoshimura, T.
AU - Fukuda, K.
AU - Okamoto, N.
AU - Shio, H.
AU - Kitagawa, T.
AU - Kuroki, T.
AU - Tajima, K.
AU - Shimamoto, T.
AU - Tanaka, H.
AU - Hisamichi, S.
AU - Nakao, M.
AU - Suzuki, T.
AU - Hashimoto, T.
AU - Ishibashi, T.
AU - Aoki, Kunio
AU - Sugano, Haruo
AU - Nakachi, Kei
AU - Hashimoto, Shuji
PY - 2002/12/1
Y1 - 2002/12/1
N2 - To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.
AB - To elucidate the roles of insulin-like growth factors (IGFs) in the development of lung cancer, we conducted a case-control study nested within the Japan Collaborative Cohort Study. Serum samples were collected at baseline from 39 140 men and women between 1988 and 1990. We measured serum IGF-I, IGF-II, and IGF-binding protein-3 (IGFBP-3) in 194 case subjects who subsequently died from lung cancer during an 8-year follow-up and in 9351 controls. The odds ratios (ORs), adjusted for smoking and other covariates, were smaller with higher levels of IGF-II and IGFBP-3. The ORs across quartiles were 0.41 (95% confidence interval [CI], 0.27-0.63), 0.47 (0.31-0.71), and 0.67 (0.46-0.98) for IGF-II (trend P=0.018), and 0.55 (95% CI, 0.37-0.81), 0.54 (0.36-0.82), and 0.67 (0.45-1.01) for IGFBP-3 (trend P=0.037). These peptides were not independently related to lung cancer risk when mutually adjusted. The risk was increased in the highest vs. the lowest quartile of IGF-I only after controlling for IGFBP-3 (OR, 1.74; 95% CI, 1.08-2.81). Limiting subjects to those followed for ≥3 years strengthened the negative associations of IGF-II and IGFBP-3, whereas the ORs for IGF-I generally decreased. A higher level of circulating IGFBP-3 and/or IGF-II may decrease lung cancer risk. Elevated serum IGF-I may increase the risk, but this could partly be attributable to latent tumors.
UR - http://www.scopus.com/inward/record.url?scp=0036958017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036958017&partnerID=8YFLogxK
U2 - 10.1111/j.1349-7006.2002.tb01235.x
DO - 10.1111/j.1349-7006.2002.tb01235.x
M3 - Review article
VL - 93
SP - 1279
EP - 1286
JO - Cancer Science
JF - Cancer Science
SN - 1347-9032
IS - 12
ER -